File Download
 
Links for fulltext
(May Require Subscription)
 
Supplementary

Article: Optimization and evaluation of an influenza A (H5) pseudotyped lentiviral particle-based serological assay
  • Basic View
  • Metadata View
  • XML View
TitleOptimization and evaluation of an influenza A (H5) pseudotyped lentiviral particle-based serological assay
 
AuthorsGarcia, JM3
Lagarde, N3
Ma, ESK2
de Jong, MD1
Peiris, JSM3 2
 
KeywordsDiagnosis
H5N1
Influenza
Pseudoparticle
Pseudotyped lentiviral particles
Serology
 
Issue Date2010
 
PublisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jcv
 
CitationJournal Of Clinical Virology, 2010, v. 47 n. 1, p. 29-33 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.jcv.2009.10.009
 
AbstractBackground: Novel serological methods provide alternative options for sero-diagnosis, sero-epidemiology and for determining evidence of naturally acquired or vaccine induced immunity. Micro-neutralization tests are currently the gold standard for serological studies of highly pathogenic avian influenza in mammalian species but require handling live virus in a biosafety level (BSL) 3 environment. We previously reported the use of H5 pseudotyped lentiviral particles (H5pp) as an alternative to micro-neutralization tests in a BSL-2 setting (Nefkens et al., 2007). Objective: To optimize and evaluate this newly developed H5pp assay on relevant clinical specimens. Study design: We optimise and evaluate the performance of the H5pp assay using well-characterized sera from humans with confirmed H5N1 disease or controls. Results: The H5pp assay is a reliable serological method for the detection and quantification of neutralizing antibody to H5-viruses. Conclusion: H5pp provide a reliable and safe alternative for sero-diagnosis and sero-epidemiology of H5N1 infections in a BSL-2 setting. © 2009 Elsevier B.V. All rights reserved.
 
ISSN1386-6532
2012 Impact Factor: 3.287
2012 SCImago Journal Rankings: 1.294
 
DOIhttp://dx.doi.org/10.1016/j.jcv.2009.10.009
 
ISI Accession Number IDWOS:000273111200007
Funding AgencyGrant Number
University Grants Committee of the Hong Kong Special Administrative Region, ChinaAoE/M-12/06
French Ministry of Health, RESPARI Pasteur network
Li Ka Shing Foundation
Funding Information:

This work was supported by the University Grants Committee of the Hong Kong Special Administrative Region, China (Project No AoE/M-12/06), the French Ministry of Health, RESPARI Pasteur network and the Li Ka Shing Foundation

 
ReferencesReferences in Scopus
 
GrantsControl of Pandemic and Inter-pandemic Influenza
 
DC FieldValue
dc.contributor.authorGarcia, JM
 
dc.contributor.authorLagarde, N
 
dc.contributor.authorMa, ESK
 
dc.contributor.authorde Jong, MD
 
dc.contributor.authorPeiris, JSM
 
dc.date.accessioned2010-12-23T08:44:51Z
 
dc.date.available2010-12-23T08:44:51Z
 
dc.date.issued2010
 
dc.description.abstractBackground: Novel serological methods provide alternative options for sero-diagnosis, sero-epidemiology and for determining evidence of naturally acquired or vaccine induced immunity. Micro-neutralization tests are currently the gold standard for serological studies of highly pathogenic avian influenza in mammalian species but require handling live virus in a biosafety level (BSL) 3 environment. We previously reported the use of H5 pseudotyped lentiviral particles (H5pp) as an alternative to micro-neutralization tests in a BSL-2 setting (Nefkens et al., 2007). Objective: To optimize and evaluate this newly developed H5pp assay on relevant clinical specimens. Study design: We optimise and evaluate the performance of the H5pp assay using well-characterized sera from humans with confirmed H5N1 disease or controls. Results: The H5pp assay is a reliable serological method for the detection and quantification of neutralizing antibody to H5-viruses. Conclusion: H5pp provide a reliable and safe alternative for sero-diagnosis and sero-epidemiology of H5N1 infections in a BSL-2 setting. © 2009 Elsevier B.V. All rights reserved.
 
dc.description.naturepostprint
 
dc.identifier.citationJournal Of Clinical Virology, 2010, v. 47 n. 1, p. 29-33 [How to Cite?]
DOI: http://dx.doi.org/10.1016/j.jcv.2009.10.009
 
dc.identifier.citeulike6198222
 
dc.identifier.doihttp://dx.doi.org/10.1016/j.jcv.2009.10.009
 
dc.identifier.epage33
 
dc.identifier.hkuros178058
 
dc.identifier.isiWOS:000273111200007
Funding AgencyGrant Number
University Grants Committee of the Hong Kong Special Administrative Region, ChinaAoE/M-12/06
French Ministry of Health, RESPARI Pasteur network
Li Ka Shing Foundation
Funding Information:

This work was supported by the University Grants Committee of the Hong Kong Special Administrative Region, China (Project No AoE/M-12/06), the French Ministry of Health, RESPARI Pasteur network and the Li Ka Shing Foundation

 
dc.identifier.issn1386-6532
2012 Impact Factor: 3.287
2012 SCImago Journal Rankings: 1.294
 
dc.identifier.issue1
 
dc.identifier.openurl
 
dc.identifier.pmid19897409
 
dc.identifier.scopuseid_2-s2.0-72049126376
 
dc.identifier.spage29
 
dc.identifier.urihttp://hdl.handle.net/10722/129963
 
dc.identifier.volume47
 
dc.languageeng
 
dc.publisherElsevier BV. The Journal's web site is located at http://www.elsevier.com/locate/jcv
 
dc.publisher.placeNetherlands
 
dc.relation.ispartofJournal of Clinical Virology
 
dc.relation.projectControl of Pandemic and Inter-pandemic Influenza
 
dc.relation.referencesReferences in Scopus
 
dc.rightsCreative Commons: Attribution 3.0 Hong Kong License
 
dc.subject.meshInfluenza A Virus, H5N1 Subtype - genetics - immunology
 
dc.subject.meshInfluenza, Human - diagnosis - immunology
 
dc.subject.meshLentivirus - genetics
 
dc.subject.meshNeutralization Tests - methods
 
dc.subject.meshVirion - genetics
 
dc.subjectDiagnosis
 
dc.subjectH5N1
 
dc.subjectInfluenza
 
dc.subjectPseudoparticle
 
dc.subjectPseudotyped lentiviral particles
 
dc.subjectSerology
 
dc.titleOptimization and evaluation of an influenza A (H5) pseudotyped lentiviral particle-based serological assay
 
dc.typeArticle
 
<?xml encoding="utf-8" version="1.0"?>
<item><contributor.author>Garcia, JM</contributor.author>
<contributor.author>Lagarde, N</contributor.author>
<contributor.author>Ma, ESK</contributor.author>
<contributor.author>de Jong, MD</contributor.author>
<contributor.author>Peiris, JSM</contributor.author>
<date.accessioned>2010-12-23T08:44:51Z</date.accessioned>
<date.available>2010-12-23T08:44:51Z</date.available>
<date.issued>2010</date.issued>
<identifier.citation>Journal Of Clinical Virology, 2010, v. 47 n. 1, p. 29-33</identifier.citation>
<identifier.issn>1386-6532</identifier.issn>
<identifier.uri>http://hdl.handle.net/10722/129963</identifier.uri>
<description.abstract>Background: Novel serological methods provide alternative options for sero-diagnosis, sero-epidemiology and for determining evidence of naturally acquired or vaccine induced immunity. Micro-neutralization tests are currently the gold standard for serological studies of highly pathogenic avian influenza in mammalian species but require handling live virus in a biosafety level (BSL) 3 environment. We previously reported the use of H5 pseudotyped lentiviral particles (H5pp) as an alternative to micro-neutralization tests in a BSL-2 setting (Nefkens et al., 2007). Objective: To optimize and evaluate this newly developed H5pp assay on relevant clinical specimens. Study design: We optimise and evaluate the performance of the H5pp assay using well-characterized sera from humans with confirmed H5N1 disease or controls. Results: The H5pp assay is a reliable serological method for the detection and quantification of neutralizing antibody to H5-viruses. Conclusion: H5pp provide a reliable and safe alternative for sero-diagnosis and sero-epidemiology of H5N1 infections in a BSL-2 setting. &#169; 2009 Elsevier B.V. All rights reserved.</description.abstract>
<language>eng</language>
<publisher>Elsevier BV. The Journal&apos;s web site is located at http://www.elsevier.com/locate/jcv</publisher>
<relation.ispartof>Journal of Clinical Virology</relation.ispartof>
<rights>Creative Commons: Attribution 3.0 Hong Kong License</rights>
<subject>Diagnosis</subject>
<subject>H5N1</subject>
<subject>Influenza</subject>
<subject>Pseudoparticle</subject>
<subject>Pseudotyped lentiviral particles</subject>
<subject>Serology</subject>
<subject.mesh>Influenza A Virus, H5N1 Subtype - genetics - immunology</subject.mesh>
<subject.mesh>Influenza, Human - diagnosis - immunology</subject.mesh>
<subject.mesh>Lentivirus - genetics</subject.mesh>
<subject.mesh>Neutralization Tests - methods</subject.mesh>
<subject.mesh>Virion - genetics</subject.mesh>
<title>Optimization and evaluation of an influenza A (H5) pseudotyped lentiviral particle-based serological assay</title>
<type>Article</type>
<identifier.openurl>http://library.hku.hk:4550/resserv?sid=HKU:IR&amp;issn=1386-6532&amp;volume=47&amp;issue=1&amp;spage=29&amp;epage=33&amp;date=2010&amp;atitle=Optimization+and+evaluation+of+an+influenza+A+(H5)+pseudotyped+lentiviral+particle-based+serological+assay</identifier.openurl>
<description.nature>postprint</description.nature>
<identifier.doi>10.1016/j.jcv.2009.10.009</identifier.doi>
<identifier.pmid>19897409</identifier.pmid>
<identifier.scopus>eid_2-s2.0-72049126376</identifier.scopus>
<identifier.hkuros>178058</identifier.hkuros>
<relation.references>http://www.scopus.com/mlt/select.url?eid=2-s2.0-72049126376&amp;selection=ref&amp;src=s&amp;origin=recordpage</relation.references>
<identifier.volume>47</identifier.volume>
<identifier.issue>1</identifier.issue>
<identifier.spage>29</identifier.spage>
<identifier.epage>33</identifier.epage>
<identifier.isi>WOS:000273111200007</identifier.isi>
<publisher.place>Netherlands</publisher.place>
<relation.project>Control of Pandemic and Inter-pandemic Influenza</relation.project>
<identifier.citeulike>6198222</identifier.citeulike>
<bitstream.url>http://hub.hku.hk/bitstream/10722/129963/1/Content.pdf</bitstream.url>
</item>
Author Affiliations
  1. UCL
  2. The University of Hong Kong
  3. HKU-Pasteur Research Centre